{"entity":{"id":"nct04969731","kind":"trial","name":"Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer","aka":[],"tldr":"A phase 3 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by GC Cell Corporation, now recruiting.","summary":"Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer is a phase 3 interventional study registered as NCT04969731 by GC Cell Corporation, with 408 participants planned, started 2021-09-07 and due to reach its primary completion in 2026-12. Interventions recorded: Immuncell-LC, Gemcitabine. Conditions listed: Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04969731","url":"https://clinicaltrials.gov/study/NCT04969731"}],"tags":["ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["gemcitabine"],"companies":["gc-cell"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04969731","phase":"3","setting":"An Open-label, Randomized, Multi-center, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Immuncell-LC Therapy Combined With Gemcitabine Versus Adjuvant Gemcitabine Single Therapy After Resection in Patients With Pancreatic Ductal Adenocarcinoma","sponsor":"GC Cell Corporation","enrolled":408,"outcomes":[]},"route":"/trials/nct04969731/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"}],"company":[{"id":"gc-cell","kind":"company","name":"GC Cell","route":"/companies/gc-cell/"}]}}